Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis Source: Eur Respir Rev 2013; 22: 476-486 Year: 2013
Inhaler choice in primary practice Source: Eur Respir Rev 2005; 14: 117-122 Year: 2005
Inhaler treatment options in COPD Source: Eur Respir Rev 2005; 14: 102-108 Year: 2005
Efficacy and safety of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011
Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs) Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011
Evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections Year: 2016
Applicability of dry powder inhalers in children with CF Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016
Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study Source: Eur Respir J 2011; 38: 1071-1080 Year: 2011
Improving inhalation parameters through dry powder inhalers (DPIs) after an acute asthma exacerbation Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Do dry powder inhalers (DPIs) have a ‘Goldilocks Zone’ of inhalation? In vitro lung deposition of Budesonide/Formoterol (BUD/FORM) DPI with different inhalation profiles Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017
Clinical equivalence of budesonide delivered via two dry powder inhalers Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
A study to evaluate the therapeutic equivalence of a new multidose budesonide dry powder inhaler with a conventional budesonide dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
Equivalence testing of salbutamol dry powder inhalers by in vitro impaction Source: Eur Respir J 2001; 18: Suppl. 33, 100s Year: 2001
Do asthma patients achieve effective dosing from dry powder inhalers (DPIs)? Source: Eur Respir J 2005; 26: Suppl. 49, 338s Year: 2005
Effect of I:E ratio on delivery of colistimethate sodium from breath-enhanced and breath-activated nebulizers Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013
Use of dry powder inhalers in COPD Source: Eur Respir J 2005; 26: Suppl. 49, 286s Year: 2005
Oral manifestations in asthmatic patients using metered dose inhaler and dry powder inhaler Source: International Congress 2019 – Innovations in primary care assessment and management Year: 2019
Efficacy and safety of salbutamol delivered via a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 50s Year: 2001
Broncho dilator response to salbutamol delivered by metered dose inhaler with spacer versus dry powder inhaler in acute asthma in children Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016